UCB S.A. UCB S.A.

UCB S.A.

UCB

Clasificación en acciones #523
UCB S.A., a biopharmaceutical enterprise founded in 1925 and headquartered in... UCB S.A., a biopharmaceutical enterprise founded in 1925 and headquartered in Brussels, Belgium, focuses on developing innovative solutions for individuals living with neurological and immunological diseases. Its diverse commercialized portfolio includes Cimzia, targeting inflammatory TNF-mediated conditions such as Crohn's disease, various forms of spondyloarthritis, rheumatoid arthritis, and psoriasis. For epilepsy management, UCB offers Vimpat, Keppra, and Briviact, along with Nayzilam, an intranasal rescue treatment for seizure clusters. Neupro is available for Parkinson's disease and restless legs syndrome, while Zyrtec and Xyzal address allergy symptoms. Other key products include Evenity for osteoporosis in postmenopausal women, and BIMZELX, which treats psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa. The company also provides dapirolizumab pegol for systemic lupus erythematosus. UCB's robust development pipeline features candidates like rozanolixizumab, aimed at myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan for myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam for prolonged seizures; Bepranemab for Alzheimer's disease; and UCB0599 for Parkinson's disease. Beyond its proprietary drug development, UCB also conducts contract manufacturing. The company engages in significant collaborations with entities such as Amgen, Biogen, Roche/Genentech, Novartis, Otsuka, and doc.ai. UCB's global footprint extends across numerous countries, including the United States, Japan, China, Belgium, and a broad presence throughout Europe, encompassing Germany, Spain, France, Italy, the United Kingdom, and Ireland.
Precio por acción
$242.33
Última sincronización: 2026-10-19
Capitalización bursátil
$46.20B
Cambio (1 día)
-0.15%
Cambio (1 año)
-17.83%
País
BE
Comercio UCB S.A. (UCB)

Categoría

Healthcare
Historial de dividendos de UCB S.A. (UCB)
UCB S.A. (símbolo bursátil: UCB) realizó un total de 29 pagos de dividendos.
La suma de todos los dividendos (ajustados por splits de acciones) es: $27.69
Rentabilidad por dividendo (TTM): 0.0072
Pagos de dividendos de UCB S.A. (UCB) desde 2000 hasta 2026
Pagos anuales de dividendos
Año Dividendo (ajustado por splits de acciones) Cambiar
2026 (TTM) $1.20 0.00%
2025 $1.20 -11.98%
2024 $1.36 2.26%
2023 $1.33 2.31%
2022 $1.30 2.36%
2021 $1.27 2.42%
2020 $1.24 2.48%
2019 $1.21 2.54%
2018 $1.18 2.61%
2017 $1.15 4.55%
2016 $1.10 3.77%
2015 $1.06 1.92%
2014 $1.04 1.96%
2013 $1.02 2.00%
2012 $1.00 2.04%
2011 $0.98 2.08%
2010 $0.96 4.35%
2009 $0.92 0.00%
2008 $0.92 2.22%
2007 $0.9 2.27%
2006 $0.88 2.33%
2005 $0.86 -34.85%
2004 $1.32 9.09%
2003 $1.21 6.14%
2002 $1.14 78.13%
2001 $0.64 28.00%
2000 $0.5 0.00%
Lista de todos los pagos de dividendos
Año Dividendo Cambiar
2026 (TTM) $1.20 0.00%
2025 $1.20 -11.98%
2024 $1.36 2.26%
2023 $1.33 2.31%
2022 $1.30 2.36%
2021 $1.27 2.42%
2020 $1.24 2.48%
2019 $1.21 2.54%
2018 $1.18 2.61%
2017 $1.15 4.55%
2016 $1.10 3.77%
2015 $1.06 1.92%
2014 $1.04 1.96%
2013 $1.02 2.00%
2012 $1.00 2.04%
2011 $0.98 2.08%
2010 $0.96 4.35%
2009 $0.92 0.00%
2008 $0.92 2.22%
2007 $0.9 2.27%
2006 $0.88 2.33%
2005 $0.86 -34.85%
2004 $1.32 9.09%
2003 $1.21 6.14%
2002 $1.14 78.13%
2001 $0.64 28.00%
2000 $0.5 0.00%
Pagos de dividendos de empresas similares o competidoras
Empresa Número de pagos de dividendos País
0.00%
US
0.00%
US
64.00%
AU
0.00%
CH
0.00%
NL